List of Excipients in Branded Drug BUDESONIDE (ENTERIC COATED)

Generic Drugs Containing BUDESONIDE (ENTERIC COATED)

Company	Ingredient	NDC	Excipient
Golden State Medical Supply Inc	budesonide	51407-128	ACETYLTRIBUTYL CITRATE
Golden State Medical Supply Inc	budesonide	51407-128	D&C RED NO. 28
Golden State Medical Supply Inc	budesonide	51407-128	D&C RED NO. 33
Golden State Medical Supply Inc	budesonide	51407-128	D&C YELLOW NO. 10
Golden State Medical Supply Inc	budesonide	51407-128	ETHYLCELLULOSE

What are the Most Frequently-Used Excipients in BUDESONIDE (ENTERIC COATED)?

# Of NDCs	Excipient
3	ACETYLTRIBUTYL CITRATE
3	D&C RED NO. 28
3	D&C RED NO. 33
3	D&C YELLOW NO. 10
3	ETHYLCELLULOSE

Budesonide Enteric-Coated Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Budesonide enteric-coated products compete through release-site control, multiparticulate performance, formulation similarity, and manufacturing reliability. The main commercial reference is Entocort EC, a delayed-release capsule containing enteric-coated budesonide granules for ileal and ascending-colon delivery. The strongest opportunities are lactose-free and low-moisture formulations, pediatric-friendly presentations, improved coating efficiency, and platform technologies that differentiate simple delayed release from site-specific colonic delivery.

What is budesonide enteric-coated technology?

Enteric-coated budesonide is an oral modified-release formulation designed to protect the drug in the stomach and release it after the dosage form reaches a higher-intestinal-pH environment.

Budesonide is a potent locally acting corticosteroid with extensive first-pass hepatic metabolism. The formulation objective is to deliver drug to the gastrointestinal tract while limiting systemic exposure. The product design has three linked elements:

1. A drug-containing core or pellet.
2. A functional barrier or sustained-release layer.
3. An enteric polymer coating that dissolves above a defined pH threshold.

Entocort EC uses hard capsules filled with enteric-coated granules. This multiparticulate structure distributes the dose throughout the gastrointestinal tract and reduces the risk that one unit failure will release the full dose prematurely.

How does enteric-coated budesonide differ from MMX budesonide?

Attribute	Enteric-coated multiparticulates	MMX or colonic matrix tablet
Commercial reference	Entocort EC	Uceris
Primary release target	Ileum and proximal colon	Colon
Dosage form	Capsule with coated granules	Extended-release tablet
Main control mechanism	Pellet coating and pH-triggered dissolution	Multi-matrix tablet with coating and matrix diffusion
Dose profile	Distributed pellet release	Tablet transit followed by colonic release
Main formulation risk	Pellet coating variability and dose dumping	Matrix erosion, coating integrity and food effects
Main market	Crohn's disease	Ulcerative colitis

A company developing "enteric-coated budesonide" should define the target product precisely. A generic Entocort-type capsule, a Uceris-type colonic tablet and a Tarpeyo-type delayed-release capsule are technically and legally different products.

What excipients are used in budesonide enteric-coated formulations?

The principal excipient classes are pellet substrates, binders, coating polymers, plasticizers, anti-tacking agents, surfactants and capsule materials.

Core excipients

The drug layer commonly uses one or more of the following:

• Sugar spheres or microcrystalline cellulose spheres
• Lactose or other water-soluble diluents
• Povidone or hydroxypropyl cellulose as a binder
• Purified water or hydroalcoholic processing solvent
• Talc or colloidal silicon dioxide as a processing aid

Sugar spheres are commercially attractive because they support uniform drug layering and produce reproducible multiparticulate size distributions. They also simplify coating equipment qualification. Their disadvantages are dependence on sugar-based raw materials and potential limitations for diabetic, low-sugar or excipient-sensitive positioning.

Microcrystalline cellulose pellets provide a lower-sugar platform and stronger mechanical integrity. They can improve resistance to attrition during fluid-bed coating, although they may produce different drug-loading and dissolution characteristics from sugar spheres.

Enteric polymers

Common enteric polymer options include:

• Methacrylic acid-ethyl acrylate copolymers
• Methacrylic acid-methyl methacrylate copolymers
• Cellulose acetate phthalate
• Hypromellose phthalate
• Polyvinyl acetate phthalate

Methacrylic acid copolymers are generally the most practical modern choice because their dissolution thresholds can be selected through polymer grade and coating composition. Lower-pH grades can support ileal release, while higher-pH grades can delay release toward the colon.

The polymer should be selected with the clinical release site in mind. A formulation that releases at pH 5.5 to 6.0 may be appropriate for distal small-intestinal or ileocecal delivery. A formulation requiring pH 7.0 or higher may provide stronger colonic targeting but can introduce greater variability because intestinal pH varies among patients and disease states.

Plasticizers and anti-tacking agents

Triethyl citrate, acetyl tributyl citrate, polyethylene glycol and related plasticizers reduce coating brittleness. Talc, glyceryl monostearate and colloidal silicon dioxide can reduce tack during fluid-bed processing.

Plasticizer selection affects:

• Film flexibility
• Coating coalescence
• Water permeability
• Storage stability
• Dissolution after gastric exposure
• Interaction with capsule shells and packaging

A coating that is too flexible may become more permeable during storage. A coating that is too brittle may crack during pellet handling, encapsulation or transport.

Surfactants and wetting agents

Polysorbate 80, sodium lauryl sulfate and lecithin may improve wetting and coating uniformity. Surfactant concentration should remain tightly controlled because changes can affect drug release, polymer film structure and dissolution after the enteric layer opens.

Capsule materials

Hard gelatin capsules are widely used for multiparticulate products. Hypromellose capsules offer a commercial alternative for:

• Vegetarian positioning
• Lower moisture interaction
• Reduced gelatin supply risk
• Improved compatibility with selected powders or pellets

Capsule-shell selection can affect moisture transfer, brittleness, disintegration and stability. A switch from gelatin to hypromellose requires comparative dissolution and stability work, even when the internal pellet system remains unchanged.

What formulation strategy offers the strongest commercial opportunity?

The strongest near-term opportunity is a robust, bioequivalent multiparticulate capsule with a differentiated excipient profile. The formulation should prioritize release performance over a novel excipient claim.

Opportunity 1: Lactose-free and low-sugar budesonide capsules

A sugar-sphere and lactose-containing platform can be replaced with microcrystalline cellulose pellets, starch-based spheres or another pharmaceutically established inert substrate.

The commercial rationale is stronger for a product that combines:

• Lactose-free composition
• Hypromellose capsule shell
• Low moisture content
• Comparable dissolution across pH conditions
• Lower risk of excipient intolerance
• Competitive manufacturing cost

The principal regulatory challenge is proving that the alternative core does not change drug layering, pellet porosity, transit behavior or in vitro release.

Opportunity 2: Pediatric multiparticulate delivery

Budesonide is used in pediatric inflammatory bowel disease, where swallowing capsules can be difficult. A commercial product could use:

• Sprinkle-compatible enteric-coated pellets
• Unit-dose sachets
• A capsule that can be opened without compromising dose uniformity
• A neutral-taste or taste-masked pellet system

Taste masking is difficult because budesonide is potent and the dose is low, but damaged or incompletely coated pellets can create a bitter mouthfeel. The product must preserve enteric performance after opening and administration with soft food or liquid.

Opportunity 3: Lower-cost coating systems

Coating cost is driven by polymer consumption, solvent or water handling, drying time, equipment utilization and yield loss. Commercial improvements can come from:

• Higher-solids aqueous coating dispersions
• Improved atomization
• Reduced coating weight
• In-line end-point monitoring
• More uniform pellet size
• Lower overspray
• Continuous fluid-bed processing

The economic value is highest where the product is sold into high-volume generic markets. Small reductions in coating weight can improve throughput, but excessive reduction can create gastric release failures or accelerated release during storage.

Opportunity 4: More precise ileocecal release

A formulation can target the ileocecal region through coordinated use of:

• Enteric-polymer dissolution threshold
• Coating thickness
• Pellet size
• Barrier-layer permeability
• Polymer blends
• Capsule disintegration behavior

A more precise release profile could support a product positioned for Crohn's disease with ileal or right-colon involvement. The clinical value must be demonstrated through pharmacokinetic, pharmacodynamic or clinical data. A dissolution distinction alone may not create meaningful market exclusivity.

Opportunity 5: Combination or sequential-release products

Budesonide pellets could be combined with other gastrointestinal therapies in a multiparticulate capsule, but the commercial and regulatory burden is high. Compatibility, dose uniformity, release interaction and clinical justification would be required.

A more practical approach is a co-packaged regimen or two-compartment presentation rather than a chemically combined capsule.

What FDA regulatory status applies to enteric-coated budesonide?

The principal U.S. reference products are:

Product	Active ingredient	Dosage form	FDA indication focus	FDA milestone
Entocort EC	Budesonide	3 mg delayed-release capsule	Mild-to-moderate Crohn's disease involving ileum and/or ascending colon	Approved under NDA 21-324 in 2001
Uceris	Budesonide	9 mg extended-release tablet	Induction of remission in ulcerative colitis	Approved under NDA 203-634 in 2013
Tarpeyo	Budesonide	4 mg delayed-release capsule	Reduction of proteinuria in primary IgA nephropathy	Approved under NDA 214-665 in 2021

FDA labels identify inactive ingredients and product-specific administration instructions. Entocort-type capsules are not interchangeable with Uceris tablets because the delivery systems, strengths, indications and release profiles differ. [1-3]

For an ANDA targeting an Entocort-type product, the key regulatory package includes:

• Pharmaceutical equivalence
• Comparative dissolution across multiple pH conditions
• Stability data
• Inactive-ingredient justification
• Bioequivalence
• Capsule content uniformity
• Particle-size and coating controls
• Demonstration of delayed release and resistance to gastric conditions

The FDA's product-specific guidance for budesonide delayed-release capsules is central to development planning. [4]

What patents protect enteric-coated budesonide products?

Patent exposure depends on the reference product, dosage form, indication and target market. The composition of matter patent for budesonide is no longer the principal barrier in the United States. Commercial protection has shifted toward formulation, delivery system, method-of-use and manufacturing patents.

Entocort-type products

Entocort EC's principal commercial barriers were historically associated with delayed-release multiparticulate delivery and methods for treating intestinal inflammatory disease. Those barriers have largely aged out in the U.S. market, enabling ANDA competition.

The relevant patent questions for a generic applicant are:

• Whether the target product is the listed reference drug
• Whether any Orange Book patent remains listed for the specific NDA
• Whether the ANDA requires Paragraph IV certification
• Whether pediatric, method-of-use or formulation claims remain enforceable
• Whether the applicant can carve out protected indications
• Whether product labeling includes a use that remains patent-protected

Orange Book status must be evaluated by NDA and product presentation, not by the active ingredient alone. [5]

Uceris-type products

Uceris has a more complex formulation estate because its extended-release tablet uses a colonic delivery architecture rather than a standard enteric-coated pellet system. Relevant patent families have addressed MMX-type matrices, coating systems, colonic delivery and treatment of ulcerative colitis.

A company targeting Uceris must review:

• Listed formulation patents
• Method-of-use patents
• Patent-term adjustment
• Pediatric exclusivity
• Paragraph IV litigation history
• Settlement restrictions
• Approved-label carve-outs

A conventional enteric-coated capsule is unlikely to be an automatic substitute for a Uceris-type tablet in regulatory, clinical or patent terms.

Tarpeyo-type products

Tarpeyo adds a separate patent and regulatory layer because the product is associated with IgA nephropathy, a different disease and a different clinical value proposition. Its delayed-release capsule technology may overlap with broader budesonide delivery concepts, but the relevant patent analysis must separate:

• Product patents
• Use patents for IgA nephropathy
• Capsule and pellet architecture
• Manufacturing claims
• Orphan-drug exclusivity
• Regulatory exclusivity

A generic or follow-on product cannot assume that an older Entocort-type formulation provides a clear path around Tarpeyo-related claims.

When does budesonide lose exclusivity?

Budesonide has already lost core active-ingredient exclusivity in the United States. The practical exclusivity timeline is product-specific.

Exclusivity category	Commercial position
Budesonide chemical entity	Expired or commercially overcome
Entocort EC delayed-release capsule	Generic competition established
Uceris extended-release tablet	Formulation and use protections require product-specific review
Tarpeyo delayed-release capsule	Later-entry product with active product, use and regulatory barriers
New pediatric or rare-disease formulation	Potential for new patents and regulatory exclusivity

FDA approval of a generic does not eliminate all litigation risk. A later entrant can still face claims covering formulation, manufacturing or a patented indication. The Paragraph IV date, notice letter, litigation filing and any 30-month stay must be analyzed for the exact ANDA and listed patents.

Which companies are challenging or competing with budesonide enteric-coated products?

Competition exists across three groups:

1. Generic manufacturers selling delayed-release budesonide capsules.
2. Branded companies using differentiated delivery systems.
3. Specialty pharmaceutical companies applying budesonide to new diseases.

The competitive landscape includes:

• Entocort-type generic capsule manufacturers
• Uceris and generic extended-release tablet suppliers
• Calliditas Therapeutics, acquired by STADA, for Tarpeyo/Nefecon-related development and commercialization
• Pharmaceutical companies developing budesonide for eosinophilic, autoimmune, renal and gastrointestinal indications
• Contract development and manufacturing organizations with fluid-bed coating and multiparticulate capabilities

The most defensible commercial position is not a generic capsule alone. It is a product with a distinct delivery site, patient-friendly administration method, regulatory advantage or indication-specific clinical evidence.

How strong is the patent estate for an enteric-coated budesonide product?

A basic enteric-coated budesonide capsule has moderate-to-low long-term patent strength because the active ingredient is old and the core technology uses established excipients and coating methods.

Patent strength improves when the product has:

• A narrowly defined release location
• A reproducible in vitro-in vivo relationship
• A proprietary pellet architecture
• A clinically demonstrated food-independent profile
• A novel manufacturing process
• A pediatric administration method
• A new indication supported by clinical data
• A formulation that reduces systemic exposure or adverse effects

Weak patent positions usually rely on broad claims covering conventional enteric polymers, standard plasticizers or routine coating steps. Stronger claims define measurable release parameters, particle-size distributions, coating-layer relationships or clinically relevant exposure outcomes.

Freedom-to-operate risk is highest where a proposed product uses a branded delivery platform rather than a conventional generic design. A design-around strategy should change the release mechanism, polymer combination, pellet substrate, coating structure or dosage-form architecture without compromising bioequivalence.

What manufacturing and IP barriers affect commercial entry?

Manufacturing capability is a meaningful barrier even when patent risk is limited.

Critical process controls

Key controls include:

• Budesonide content uniformity during drug layering
• Pellet-size distribution
• Coating weight gain
• Spray rate and atomization pressure
• Inlet and outlet temperature
• Residual solvent or moisture
• Gastric-stage acid resistance
• Buffer-stage release
• Pellet friability
• Capsule-fill weight
• Stability under high humidity

Budesonide is used at low dose, making content uniformity and drug-layering efficiency especially important. Overcoating can delay release and increase cost. Undercoating can cause premature gastric release.

Supply-chain exposure

The main supply risks involve:

• Enteric polymer availability
• Pharmaceutical-grade pellet substrates
• Plasticizer supply
• Hypromellose capsule capacity
• Fluid-bed coating equipment
• Qualified analytical methods
• Packaging that controls moisture transfer

A formulation using several proprietary excipient grades may have a higher procurement risk than a formulation built around widely available compendial materials. The commercial advantage of a novel excipient is limited if it requires lengthy qualification or creates regulatory comparability issues.

What is the commercial opportunity by market segment?

Segment	Opportunity	Main barrier
U.S. generic Entocort-type capsule	Volume and manufacturing efficiency	Price erosion and bioequivalence
Lactose-free capsule	Differentiated generic positioning	Need for comparable release and stability
Pediatric sprinkle product	Patient convenience and adherence	Taste, dose uniformity and labeling
Uceris-type colonic tablet	Higher formulation value	MMX technology and patent exposure
Tarpeyo-type renal product	Higher clinical value per patient	Product, use and regulatory exclusivity
Emerging-market delayed-release capsule	Lower-cost local supply	Registration and quality-system requirements
Contract manufacturing	Coating and pellet-platform revenue	Capital intensity and process transfer

Revenue exposure is greatest in products tied to chronic inflammatory disease and specialty indications. Generic capsule revenue generally declines after multiple entrants, while differentiated products can preserve pricing through clinical positioning, specialty distribution or regulatory exclusivity.

How should an excipient strategy be designed?

A practical development strategy should use a staged decision process.

Stage 1: Define the target release site

Choose between:

• Ileal and proximal-colon release
• Broad delayed release
• Distal-colon delivery
• Renal indication-specific delayed release

The release target determines polymer grade, coating thickness, pellet size and dissolution specification.

Stage 2: Select a platform with regulatory precedent

A methacrylic-acid-copolymer system with established pharmaceutical use generally offers lower regulatory risk than a novel polymer. Aqueous dispersion systems can reduce solvent-handling burdens, while organic systems may provide faster film formation but create residual-solvent and facility requirements.

Stage 3: Establish a Q3 strategy

The formulation should compare:

• Particle size
• Surface area
• Porosity
• Polymer composition
• Plasticizer level
• Coating thickness
• Capsule shell type
• Moisture content
• Dissolution profile

For an ANDA, the objective is pharmaceutical equivalence and bioequivalence. For a 505(b)(2) or new product, the objective may be a clinically differentiated exposure or release profile.

Stage 4: Build claims around measurable performance

Patent claims should focus on:

• Release at defined pH intervals
• Defined gastric resistance
• Pellet size and coating weight
• Low systemic exposure
• Reduced food effect
• Specific administration with food or soft material
• Manufacturing parameters linked to release performance

Claims limited to "budesonide with an enteric coating" face substantial validity and design-around risk.

Key Takeaways

• Entocort EC is the main commercial model for enteric-coated multiparticulate budesonide.
• Uceris and Tarpeyo use distinct delivery and regulatory strategies and should not be treated as interchangeable enteric-coated products.
• The most useful excipient options are methacrylic acid copolymers, triethyl citrate or comparable plasticizers, talc or anti-tacking agents, and sugar-sphere or microcrystalline-cellulose pellet cores.
• Lactose-free, low-sugar, hypromellose-capsule and pediatric sprinkle formats offer the clearest formulation opportunities.
• Core budesonide exclusivity has expired, but product-specific formulation, method-of-use, regulatory and manufacturing barriers can remain.
• Patent value is strongest when claims cover a defined release profile, delivery site, clinical benefit or manufacturing-control relationship.
• Fluid-bed coating capability, content uniformity and moisture control are material commercial barriers.
• A basic generic capsule is exposed to price erosion. A differentiated delivery system or new indication offers greater margin potential.

FAQs

Is enteric-coated budesonide the same as delayed-release budesonide?

Usually, the terms describe a dosage form designed to resist gastric release and release later in the gastrointestinal tract. Regulatory equivalence depends on the specific product, coating system, dissolution profile and approved labeling.

Which enteric polymer is best for budesonide?

Methacrylic acid copolymers are often the most practical because their dissolution thresholds and pharmaceutical precedent support controlled intestinal release. The optimal grade depends on the intended release site.

Can lactose be removed from an Entocort-type budesonide capsule?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, starch-based materials or another suitable diluent, but the modified product must preserve pellet integrity, content uniformity, dissolution and bioequivalence.

Does an enteric coating create new budesonide patent protection?

An enteric coating alone usually provides limited patent strength when it uses known polymers and routine processing. Stronger protection requires a specific release architecture, measurable performance limitation or clinically supported use.

What is the highest-value formulation opportunity for budesonide?

A pediatric-friendly, sprinkle-compatible, lactose-free multiparticulate product or a clinically validated colon-targeted formulation has greater differentiation potential than an undifferentiated delayed-release capsule.

References

1. U.S. Food and Drug Administration. (2023). Entocort EC (budesonide) delayed-release capsules: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Uceris (budesonide) extended-release tablets: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Tarpeyo (budesonide) delayed-release capsules: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Product-specific guidance for budesonide delayed-release capsules. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters for dissolution, drug release and pharmaceutical dosage forms. USP.

7. European Medicines Agency. (2022). Assessment report and product information for budesonide modified-release gastrointestinal products. EMA.